133 related articles for article (PubMed ID: 11345951)
21. Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence.
Pfister C; Moore L; Allard P; Larue H; Lacombe L; Têtu B; Meyer F; Fradet Y
Clin Cancer Res; 1999 Dec; 5(12):4079-84. PubMed ID: 10632343
[TBL] [Abstract][Full Text] [Related]
22. Molecular abnormalities of p53, MDM2, and H-ras in synovial sarcoma.
Oda Y; Sakamoto A; Satio T; Kawauchi S; Iwamoto Y; Tsuneyoshi M
Mod Pathol; 2000 Sep; 13(9):994-1004. PubMed ID: 11007040
[TBL] [Abstract][Full Text] [Related]
23. The role of p53, MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer.
Korkolopoulou P; Christodoulou P; Kapralos P; Exarchakos M; Bisbiroula A; Hadjiyannakis M; Georgountzos C; Thomas-Tsagli E
Pathol Res Pract; 1997; 193(11-12):767-75. PubMed ID: 9521509
[TBL] [Abstract][Full Text] [Related]
24. Clinical significance of mdm2 and p53 expression in bladder cancer. A comparison with cell proliferation and apoptosis.
Shiina H; Igawa M; Shigeno K; Yamasaki Y; Urakami S; Yoneda T; Wada Y; Honda S; Nagasaki M
Oncology; 1999 Apr; 56(3):239-47. PubMed ID: 10202280
[TBL] [Abstract][Full Text] [Related]
25. p53, p21, Rb and mdm2 oncoproteins. Expression in normal placenta, partial and complete mole, and choriocarcinoma.
Fulop V; Mok SC; Genest DR; Gati I; Doszpod J; Berkowitz RS
J Reprod Med; 1998 Feb; 43(2):119-27. PubMed ID: 9513873
[TBL] [Abstract][Full Text] [Related]
26. p53 over-expression identifies a subset of nodal peripheral T-cell lymphomas with a distinctive biological profile and poor clinical outcome.
Pescarmona E; Pignoloni P; Puopolo M; Martelli M; Addesso M; Guglielmi C; Baroni CD
J Pathol; 2001 Oct; 195(3):361-6. PubMed ID: 11673835
[TBL] [Abstract][Full Text] [Related]
27. The molecular markers for prognostic evaluation of areca-associated buccal squamous cell carcinoma.
Liu CJ; Chang KW; Chao SY; Kwan PC; Chang SM; Yen RY; Wang CY; Wong YK
J Oral Pathol Med; 2004 Jul; 33(6):327-34. PubMed ID: 15200480
[TBL] [Abstract][Full Text] [Related]
28. Prospects for optimized clinical management of bladder cancer by application of phenotypic markers.
Millikan RE; Logothetis CJ
J Natl Cancer Inst; 1998 Jul; 90(14):1028-9. PubMed ID: 9672249
[No Abstract] [Full Text] [Related]
29. Status of p53, p21, mdm2, pRb proteins, and DNA methylation in gonocytes of control and gamma-irradiated rats during testicular development.
Moréno SG; Dutrillaux B; Coffigny H
Biol Reprod; 2001 May; 64(5):1422-31. PubMed ID: 11319147
[TBL] [Abstract][Full Text] [Related]
30. Deletion of p21 cannot substitute for p53 loss in rescue of mdm2 null lethality.
Montes de Oca Luna R; Amelse LL; Chavez-Reyes A; Evans SC; Brugarolas J; Jacks T; Lozano G
Nat Genet; 1997 Aug; 16(4):336-7. PubMed ID: 9241268
[No Abstract] [Full Text] [Related]
31. Frequent and heterogeneous expression of cyclin-dependent kinase inhibitor WAF1/p21 protein and mRNA in urothelial carcinoma.
Clasen S; Schulz WA; Gerharz CD; Grimm MO; Christoph F; Schmitz-Dräger BJ
Br J Cancer; 1998 Feb; 77(4):515-21. PubMed ID: 9484805
[TBL] [Abstract][Full Text] [Related]
32. Loss of nuclear p53 protein in preneoplastic rat hepatocytes is accompanied by Mdm2 and Bcl-2 overexpression and by defective response to DNA damage in vivo.
Van Gijssel HE; Ohlson LC; Torndal UB; Mulder GJ; Eriksson LC; Porsch-Hällström I; Meerman JH
Hepatology; 2000 Oct; 32(4 Pt 1):701-10. PubMed ID: 11003613
[TBL] [Abstract][Full Text] [Related]
33. p53 gene status and expression of p53, mdm2, and p21Waf1/Cip1 proteins in colorectal cancer.
Veloso M; Wrba F; Kaserer K; Heinze G; Magalhães A; Herbst F; Teleky B
Virchows Arch; 2000 Sep; 437(3):241-7. PubMed ID: 11037343
[TBL] [Abstract][Full Text] [Related]
34. Drug-resistant breast cancer cells frequently retain expression of a functional wild-type p53 protein.
Gudas JM; Nguyen H; Li T; Sadzewicz L; Robey R; Wosikowski K; Cowan KH
Carcinogenesis; 1996 Jul; 17(7):1417-27. PubMed ID: 8706243
[TBL] [Abstract][Full Text] [Related]
35. Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer.
Sjöström J; Blomqvist C; Heikkilä P; Boguslawski KV; Räisänen-Sokolowski A; Bengtsson NO; Mjaaland I; Malmström P; Ostenstadt B; Bergh J; Wist E; Valvere V; Saksela E
Clin Cancer Res; 2000 Aug; 6(8):3103-10. PubMed ID: 10955790
[TBL] [Abstract][Full Text] [Related]
36. Immunoreactivity of p53, mdm2, and p21WAF1 in dedifferentiated liposarcoma: special emphasis on the distinct immunophenotype of the well-differentiated component.
Adachi T; Oda Y; Sakamoto A; Saito T; Tamiya S; Masuda K; Tsuneyoshi M
Int J Surg Pathol; 2001 Apr; 9(2):99-109. PubMed ID: 11484509
[TBL] [Abstract][Full Text] [Related]
37. p53 and p53-regulated genes in bladder cancer.
Keegan PE; Lunec J; Neal DE
Br J Urol; 1998 Nov; 82(5):710-20. PubMed ID: 9839588
[No Abstract] [Full Text] [Related]
38. Malignant peripheral nerve sheath tumours: high Ki67 labelling index is the significant prognostic indicator.
Watanabe T; Oda Y; Tamiya S; Kinukawa N; Masuda K; Tsuneyoshi M
Histopathology; 2001 Aug; 39(2):187-97. PubMed ID: 11493336
[TBL] [Abstract][Full Text] [Related]
39. Spontaneous apoptosis of Reed-Sternberg and Hodgkin cells; clinical and pathological implications in patients with Hodgkin's disease.
Smolewski P; Niewiadomska H; Los E; Robak T
Int J Oncol; 2000 Sep; 17(3):603-9. PubMed ID: 10938405
[TBL] [Abstract][Full Text] [Related]
40. p53, WAF1/CIP1 and mdm2 expression in skin lesions associated with human papillomavirus and human immunodeficiency virus.
Arany I; Yen A; Tyring SK
Anticancer Res; 1997; 17(2B):1281-5. PubMed ID: 9137486
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
